Axsome Therapeutics Stock Filter Stocks by Fundamentals
| AXSM Stock | USD 67.90 2.18 3.32% |
Axsome Therapeutics fundamentals help investors to digest information that contributes to Axsome Therapeutics' financial success or failures. It also enables traders to predict the movement of Axsome Stock. The fundamental analysis module provides a way to measure Axsome Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Axsome Therapeutics stock.
Axsome | Cash and Equivalents |
Axsome Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Axsome Therapeutics from analyzing Axsome Therapeutics' financial statements. These drivers represent accounts that assess Axsome Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Axsome Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.5B | 3.0B | 1.4B | 3.1B | 3.6B | 3.8B | |
| Enterprise Value | 3.3B | 2.9B | 1.4B | 3.0B | 3.4B | 3.6B |
Axsome Fundamentals
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.88) % | ||||
| Operating Margin | (0.78) % | ||||
| Current Valuation | 3.1 B | ||||
| Shares Outstanding | 47.37 M | ||||
| Shares Owned By Insiders | 17.12 % | ||||
| Shares Owned By Institutions | 83.33 % | ||||
| Number Of Shares Shorted | 7.65 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 17.15 X | ||||
| Price To Sales | 12.11 X | ||||
| Revenue | 270.6 M | ||||
| Gross Profit | 45.94 M | ||||
| EBITDA | (176.07 M) | ||||
| Net Income | (239.24 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 186.37 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (145.08 M) | ||||
| Short Ratio | 8.86 X | ||||
| Earnings Per Share | (5.27) X | ||||
| Target Price | 123.0 | ||||
| Number Of Employees | 545 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 3.11 B | ||||
| Total Asset | 588.24 M | ||||
| Retained Earnings | (835.57 M) | ||||
| Working Capital | 365.41 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 588.24 M |
About Axsome Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axsome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Axsome Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Axsome Stock
| 0.86 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.84 | ME | 23Andme Holding | PairCorr |
Moving against Axsome Stock
| 0.82 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.7 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.7 | DSGN | Design Therapeutics Downward Rally | PairCorr |
| 0.62 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.6 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Axsome Therapeutics Piotroski F Score and Axsome Therapeutics Altman Z Score analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Axsome Stock analysis
When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.27) | Revenue Per Share 5.957 | Quarterly Revenue Growth 1.935 | Return On Assets (0.25) | Return On Equity (1.59) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.